Try our Advanced Search for more refined results
Life Sciences - February, 2020
295 articles
- Justices Partially Stay Generic Drug Price-Fixing Discovery
- Maverick Funds Sue Bausch Claiming Valeant Price-Gouging
- Sanofi To Pay $12M To End Mass. Medicare Kickback Probe
- Cardinal Health Pays Nearly $9M To Resolve FCPA Claims
- Coronavirus Abounds In Risk Disclosures As Disease Spreads
- FDA Clears First Generic For Daraprim
- Cannabis Bill Roundup: Virginia Is Eyeing Legal Pot
- Mallinckrodt, Express Scripts Can't Get Ill. City's Atty Fee Info
- Illumina Sues Chinese Rival, Again, For 'Brazen Infringement'
- FDA Clashes With Vape Groups As E-Cig Deadline Nears
- Becton Hit With Stock Suit Following $59M Pump Recall
- Fenwick Guides Passage Bio In Upsized, $216M Debut
- Health Hires: Ropes & Gray, K&L Gates, Abrams Fensterman
- J&J Says CEO Questioning Voids $186M Asbestos Trial Award
- Legal Industry Should Pursue AI Prediction Progress
- Judge Says Attys Didn't 'Get The Message,' Can't Drop Clients
- J&J Hit With $9M Asbestos-In-Talc Verdict, First In Fla.
- Surescripts Can't Limit Discovery In FTC Case
- UK Judge Condemns Hasty Patent Law Approach In NJ Talk
- Top DOJ Atty Spotlights Main FCA Target Areas For 2020
- Justices Urged To Ax Fed. Circ. Doctrine Of Equivalents Rule
- Opioid Cos. Slam Atty Fee Proposal That Could Reach $3.3B
- Chancery Tosses Most Of Medical Device Co.'s Sabotage Suit
- Sex Pills Don't Merit Lower VAT As Food, Top EU Court Told
- Quinn Emanuel Adds Ex-Haug Partners' Life Science Chair
- No Jail Time For 2nd Cooperator In PixarBio Fraud Scheme
- King & Spalding Brings On 2 Trial Attys From Orrick
- PTAB Says Prior Art In Pain Treatment Case Is Authentic
- Uncertainty Surrounds Legality Of Different CBD Forms
- Justices Seem Poised To Increase Cos.' Liability Overseas
- Court Certifies RICO, State Antitrust Classes In EpiPen MDL
- Trial Strategy Isn't Malpractice, Brown Rudnick Tells NY Court
- What ACA's Uncertain Future Means For Biologics Patents
- Investor Settlements Remain High As Defendant Sizes Grow
- Zest Soap Maker's $120M Sales OK'd Despite Bidder Dispute
- Ore. Tax Court Nixes Pot Biz's Deduction Before Decoupling
- IVF Investors Can Seek Discovery For Chinese Arbitration
- Real Estate Rumors: Wells, MMG Equity, Horizon Therapeutics
- Veeva Looks To Widen Antitrust Claims Against IQVIA
- Md. Medical Pot Application Process Is Broken, Suit Says
- Jury Kills HIV Test Patent That PTAB Refused To Review
- UnitedHealth Calls Medical Device Co.'s $5M Suit 'Extreme'
- Opioid Judge Rips Pharmacies' 'Ironic' Push To Halt Discovery
- Fed. Circ. Amgen Biosimilar Ruling Raises IP Damages Risk
- Solutions To 4 Common Law Firm Diversity Challenges
- Allergan Inks $51M Deal To End Direct Buyers' Restasis Suit
- Gov't Bid To Undo Arthrex-Based Remand Flops At Fed. Circ.
- 5 AGs To Lead Multistate Probe Into Juul's Marketing Tactics
- Fed. Circ. Won't Rehear Partial Ax Of Horizon Arthritis Drug IP
- Biogen Saleswoman's $6M Firing Award Trimmed To $3.5M
- Ark. Tells High Court ERISA Doesn't Nullify Drug-Payment Law
- Judge Tosses Calif. CBD Co.'s Libel Suit Against Writer
- Seyfarth Brings Litigator To Chicago Health Care Practice
- Feds Say Insys' Kapoor Should Be On Hook For $60M Tab
- When Coronavirus May Trigger SEC Disclosure Requirements
- WilmerHale Snags Capital Markets Partner From Gibson Dunn
- Drug Approval Law Will Likely Deter Pharma Delay Tactics
- Discrimination Cases Are Too Complex For AI Fee Prediction
- Fresenius Loses 'Unduly Speculative' Generic Drug Row
- Mass. High Court Takes Up Boston Drug Test Indemnity Case
- J&J Cuts Last-Minute Deal To Avert Asbestos-In-Talc Trial
- Mallinckrodt Strikes $1.6B Deal To Exit Opioid Suits
- 37 AGs Assail Plaintiffs' Atty Fee Bid In Opioid MDL
- Justices Rebuff Fraud Conviction, ADA Cases
- 9th Circ. Refuses To Block Calif. Pay-For-Delay Ban
- Architect Of Opioid MDL 'Negotiation Class' Dies Suddenly
- Genzyme Medical Device Suit Heads To Mass. High Court
- PTAB Won't Review 2 More HHS HIV-Prevention Patents
- Justices Pass On $550M Self-Dealing Claims In Mesh MDL
- Courts May Clash With Litigants Over Document Review Tech
- Proposed Privacy Laws Put Genetic Testing Cos. In Hot Seat
- High Court Won't Take Fidelity Brokerage Immunity Case
- Latest IPR Trends Mostly Favor Patent Owners
- Bankrupt High Ridge Sells Off Zest, Reach Brands
- CMS, Wilson Sonsini-Led Companies Get SoftBank Backing
- Insys Should Pay Half Of $57M Restitution, Founder Says
- High Court Won't Wade Into Walgreens Religious Bias Case
- Fish & Richardson Names Biosimilars Litigator As New CEO
- Purdue Picks Ex-USDA Head As Monitor In Bankruptcy
- Okla. Plans To Take Opioid Litigation To State Court
- Opioid Cos. Must Face Benefit Plans' Suit In MDL
- AstraZeneca Stuck With FCA Case Over Crestor Marketing
- Ad Watchdog Asks FTC To Review Co.'s CBD Health Claims
- NY Drug Biz Says Insurer Can't 'Flee' Coverage Of Legal Fees
- Vape Co. To Send FDA Deadline Challenge Row To 6th Circ.
- 3rd Circ. Says J&J Must Face Walgreens, Kroger Antitrust Suit
- Melinta's Ch. 11 Plan Docs Approved With New Information
- Trump Heads To India With Tempered Trade Expectations
- NJ Justices Will Take On J&J's Insurance Premium Tax Battle
- Pharma Ruling Broadens Gov't Drug Procurement Options
- Teva Floated As Bellwether In Generic Drug Price-Fixing MDL
- SoClean Wants To Bar 'Knockoff' CPAP Cleaner From Expo
- Feds Want 1st Circ. To Back Convictions Of Ex-NECC Execs
- Health Hires: Davis Wright, Skadden, Holland & Knight
- AI Can't Accurately Predict Case Length And Cost — Yet
- Apotex Suit Against Pfizer Unit Teed Up For State Court
- Ferring Calls Ex-USPTO Chief's Testimony A 'Waste Of Time'
- Schemer Gets 6 Mos. For Playing PixarBio's Fraud 'Game'
- 1st Circ. Won't Nix Fraud Scheme Conviction Over Google Info
- Alcon Can't Clear New Contact Lens Price-Fixing Claims
- Ex-Pfizer VP Owed No Warning On Pension Tax, Fidelity Says
- Leak Triggers Call For Sanctions In Priest's Short-Selling Suit
- Rival Says Allergan Muscle Toner Not As Strong As Claimed
- Patients Can't Revive RICO Claims Against Insulin Makers
- Abbott Can't Nix Suit Over Losing Out On $50M Merger Bonus
- Sens. Tell Azar That FDA's Deadline For Vapes Isn't Flexible
- Utah Justices Revive Suits Alleging Needless Heart Surgeries
- 1st Circ. Revives Worker's FCA Claims Against PharMerica
- 'Vague' Fee Entries Targeted In Boston Scientific FCA Suit
- DST Wants 401(k) Participants' Attys DQ'd In ERISA Fight
- Vape Cos. Tell 5th Circ. FDA Has No Right To Regulate E-Cigs
- IQVIA Calls For Sanctions After Docs 'Magically Disappeared'
- CBD Co. Says It Couldn't Have Stolen Cream Formula
- 20 Attys Picked To Lead Calif. Suits Against Juul
- PTAB Upholds Most Of J&J Unit's Robotic Surgical Patent
- FDA-FTC Biosimilar Push Clarifies Antitrust Stance
- Prop 65 Chemical Labeling Litigation: Trends And Predictions
- Ill. Says Walgreens Bilked It Out Of $19M In Autorefills Fight
- Pot Shop Wants Mass. City Sanctioned For Flouting Injunction
- Glaxo Says FDA Call About Zofran Suits Not 'Covert Lobbying'
- Investor Sues Ex-MiMedx Execs Over Book-Cooking Scheme
- Vanda Pharma Derivative Suit Will Stay In Delaware, On Ice
- 5th Circ. Affirms Lab's $30.6M Tab In Medicare Fraud Suit
- ITC Bans Bio-Rad DNA Product Imports In Patent Case
- Former Teva Exec Calls AGs' Price-Fixing Claims 'Threadbare'
- Hagens, Pomerantz, Rosen To Lead Canopy Stock-Drop Suit
- KKR Lands $200M For New Drug Therapy Research Group
- AI Offers 'Substantial' Pros At USPTO, But Not Without Risks
- States Rip Opioid Judge For Creating Class Action By 'Decree'
- 3 Cos. Join IPO Pipeline With Filings Totaling $286M
- Australis Calls Off Merger With Embattled CBD Co. Folium
- What Health Care FCA Trends Tell Us About The Year Ahead
- Amgen, Amneal Tell Fed. Circ. To Redo Sensipar IP Ruling
- Lawyers Can Build Trust Through The Spoken Word
- Ill. Consumers Say Walgreens Sold Toxic Blood Pressure Drug
- Fed. Circ. Instructive On Transitional Phrases In Patent Claims
- Ex-NFLer Says New Tests Not Needed In Pain Pump Case
- Fenwick-Led Passage Bio Launches $126M IPO
- 'Oblivious' PixarBio CEO Gets 7 Years For $7.5M Stock Fraud
- Nevada Gov. Taps Ex-Chief Justice For State Cannabis Board
- 7th Circ. Won't Revive Antrim Generic-Drug Supply Suit
- Ranbaxy Can't Ask 1st Circ. To Toss Drug Buyers' Suit
- Melinta's Ch 11. Consolidation Is 'Unjustified,' Objectors Say
- FTC Clears $5B Veterinary Hospital Deal With Location Sales
- Insys Execs Owe $57M To Insurers And Victims, Judge Rules
- 1st Circ. Revives Sanofi Insulin Injector Antitrust Case
- What Attys Should Know As Juul Battles Blaze Of Litigation
- Endo Shareholders' Price-Fixing Claims Can't Sway Judge
- Ex-Parchem Worker Dodges Trade Secrets Theft Suit
- Stryker Unit Seeks Ax Of Acantha's IP Marking Failure Suit
- Israeli Drugmaker Can Intervene In $163M Perrigo-US Row
- DOJ's Generic Drug Criminal Probe Snares Ex-Sandoz Exec
- Taxation With Representation: Latham, Skadden, Wachtell
- Fortis Loses 2nd Bid For $425M Post-Merger Drug Payout
- High Court Denies Sanofi Stay During Bid To Expand Arthrex
- Legal Prediction Is Demanding But Not Impossible
- 6th Circ. Halts Nationwide Discovery In Opioid MDL
- PTAB Questions Caris' Word Use In Cancer Treatment Patent
- Chancery Drops Suit Over Biopharma Firm's Cholesterol Drug
- Okla. Tribe Sues Gov't To Offset Opioid 'Bad Men' Harms
- Dental Suppliers Shut Down Patient Antitrust Litigation
- Pharmacies Must Give Patient Ages In Opioid MDL Discovery
- Medical Pot Shouldn't Squelch Pa. Housing Aid, Court Told
- Trends In Recent FCPA And Cartel Cases Against Execs
- Cancer Biotech's Upsized $238M IPO Leads Three Deals
- J&J Unit Settles Noncompete Dispute With Texas-Based Rival
- Class Actions Are A Growing Risk For CBD Cos.
- Life Sciences Group Of The Year: Sidley
- Coronavirus Drug Shows Global Hurdles To Patent Protection
- DLA Piper Adds Product Liability Trio To NY Office
- Akorn Poised For Ch. 11 Sale Following Failed $4.3B Merger
- Calif. Says Man's $78M Roundup Verdict Not Preempted
- Purdue Wants To Make New Opioid Overdose Drug
- Workers Lean On 8th Circ. In 2nd Circ. Express Scripts Suit
- Vape Makers' Challenge To FDA E-Cig Rule Tossed
- Amgen Sues Pfizer, Hospira As Neulasta Patent Feud Widens
- States Lead The Way On Drug Pricing Reform
- Novartis Taps Firms Ready To Pony Up On Diversity — Or Else
- Stimwave Founder Wants Legal Fees For Misconduct Suit
- Fed. Circ. May Limit USPTO's Standing To Intervene
- Fla. Orchid Grower Can't Challenge Medical Pot Licenses
- How Cos. Can Prepare For Heartburn Drug Cancer Claims
- 9th Circ. Halts Teen Suicide Suit Against Allergan
- Ex-Theranos CEO Escapes Charges She Defrauded Doctors
- PTAB Upholds Corcept Patent For Cushing's Syndrome Drug
- Life Sciences Group Of The Year: Latham
- Juul Tried To Recruit Miley Cyrus To Woo Kids, Mass. AG Says
- Justices Halt Ax Of Sanofi's Insulin Patents Over Arthrex
- Danger Of CEO Testimony Clear In $186M J&J Talc Verdict
- Ga. City Joins Chorus Decrying Skyrocketing Baby Med Price
- Shire 'Downright Mean' In Seeking Sanctions, Atty Says
- Saxena White, Bernstein Litowitz Seek Lead In Med Co. Suit
- Hospira Asks Full Fed. Circ. To Settle Split On Inherency
- Diagnostic Co. Investors Try To Seal $2.1M Stock-Drop Deal
- Tenet Settles FCA Suit Over Needless Pacemakers For $1.4M
- UK Supreme Court Weighs Patent Disclosure In Mice Row
- The Implications Of USMCA For Biologic Innovation
- Malpractice Landscape Is Becoming Riskier For BigLaw
- Life Sciences Group Of The Year: King & Spalding
- The Long Odds Of Obtaining IPR Reversals On Issues Of Fact
- Latham Reps Cancer Biotech's Upsized $231M IPO
- Fed Circ. Says Drug Ingredient Doesn't Decide Product Origin
- Ex-Theranos CEO Says Bad Blood Tests Are A 'Fact Of Life'
- Pa. Is Latest State To Claim Juul Marketed E-Cigs To Teens
- Bayer Wants $87M Roundup Cancer Trial Award Overturned
- Hemp Co. Says FDA Statements Don't Make CBD Wares Illegal
- Coronavirus Woes Tip Drug Co. Into Del. Ch. 11
- Judging A Book: Humetewa Reviews 'Guilty People'
- EPA Hemp Pesticide Approval Is A Big Step For Cannabis
- Federal-State Employment Law Divide Reveals Systemic Flaw
- Medical Tech Atty Joins Morgan Lewis As Partner In DC Office
- Melinta Gets Nod For Ch. 11 Auction Starting At $140M
- Acer Therapeutics Tries To Shake Suit Over FDA Rejection
- Life Sciences Group Of The Year: Fish & Richardson
- Pharma Co. Says Insurer HDI Global Won't Cover Ad Suit
- DOJ 'Not Done' With Generic Drug Price-Fixing
- Opioid MDL 'Negotiation Class' Gets Bombarded At 6th Circ.
- Ill. City Says Its Counsel Fees Are Off-Limits In Drug Price Suit
- Health Hires: Bradley Arant, Mintz, Brouse McDowell
- Optum Upends Coventry's $614M PBM Services Contract
- Ex-BioChemics CEO Tries To Slip 'Unfair' Disclosure Order
- CBD Maker Says FDCA Nixes Consumers' Illegal Products Suit
- Biotech Co. Loses Contempt Bid In Bovine Breeding IP Suit
- Life Sciences Group Of The Year: Covington
- UK Litigation Roundup: Here's What You Missed In London
- Takeda Beats Rivals' Challenge To Diabetes Drug Patent
- Twist Bio To Pay $22.5M To End Agilent Trade Secrets Suit
- Bayer Can't Seal Internal Essure Docs, Judge Says
- PharMerica Can't Ditch FCA Suit Over Altered Prescriptions
- J&J Unit Secures Duty-Free Treatment For HIV Drug
- Pay-For-Delay Ban Risks 'Endless Litigation,' 9th Circ. Told
- Deals Rumor Mill: Atotech, Swissport, SoftBank
- More Biotech Firms Going Public Through Blank-Check IPOs
- Takeaways From DOJ Fraud Section's Enforcement Uptick
- Biogen MS Drug Patent Survives Mylan's PTAB Challenge
- The US Product Liability Issues Spreading To The EU
- Casper And 2 Life Sci Cos. Raise Combined $482M In IPOs
- FDA Begins Crackdown On Illegally Marketed E-Cigarettes
- Cyber Liability Insurance Is Gaining Value For Cannabis Cos.
- Mass. Employment Doctrine May Not Help Ex-NuVasive Rep
- J&J Hit With $186M In Punitive Damages For Asbestos In Talc
- Akorn Can't Duck Investor Suits Over Collapsed $4.3B Merger
- PPD Raises Hefty $1.6B In Simpson Thacher-Led IPO
- Mylan Says Amendment Feedback Doesn't Save Sanofi IP
- Zofran Plaintiffs Say GSK Hid FDA Lobbying From Discovery
- JPML Ships Opioid Bellwethers Over Drug Co. Protests
- J&J Rigged Tests To Hide Asbestos In Talc, Jury Told
- Illumina Beats Claims Its Attys Deceived PTAB, Fed. Circ.
- Pot Giant Loses Ohio Licensing Battle With Cresco, Harvest
- ITC To Review Patent Dispute Between Biotech Firms
- Telemedicine Execs Charged In $56M Medicare Fraud Scheme
- Gilead's IPR Bid Over 2 Gov't HIV-Prevention Patents Fails
- Juul Targeted 8 Native American Tribes, House Report Finds
- Pet CBD Maker Hits Hemp Shop With TM Suit Over Name
- DLA Piper Snags 3 IP Attys From Cooley And Impax Labs
- Alphabet's Missteps Offer Crisis Management Case Study
- The Dollars And Sense Of Antitrust Class Certification: Part 1
- For Employers, Devil Is In Details Of Fla. Marijuana Bill
- Casper Sleep Cuts IPO Price While Beam Lifts Target
- Nestlé Unit Invests Another $200M In Food Allergy Drug Co.
- Verana Health Nabs $100M Investment, Buys PYA Analytics
- State Of The Union: Drug Prices, China Deal, Infrastructure
- 3rd Generic Drug Executive Indicted For Price-Fixing
- Fed. Circ. Mulls Reviving Fight Over Opioid Blocker Patent
- FDA Didn't Vet Enviro Impact Of GMO Salmon, Group Claims
- 1 Firm Grabs Spotlight In January Bolstered By Reynolds IPO
- Fed. Circ. Skeptical Sovereign Immunity Bars Cancer IP Suit
- SEC Inks Partial Deal With Ex-Outcome Health Exec
- Philip Morris Escapes Shareholder Suit Over E-Cig Sales
- Walgreens To Pay $7.5M To End Suit Over Fake Pharmacist
- How Emotional Intelligence Can Benefit Transactional Attys
- Insys Execs Say Assumptions Don't Equal $300M Restitution
- Why I Became A Lawyer: Following A Serendipitous Path
- LabCorp Unit Collective Action Needs More Info, Judge Says
- Pa. Court Can't Ban Medical Pot For Probationers, ACLU Says
- 2nd Circ. Asked To Redo 'Deeply Troubling' Blaszczak Ruling
- Magellan Health Taps REIT Pro As New General Counsel
- Duke Can't Get Arthrex-Based Redo Over Muscle Treatment IP
- NM Medical Pot Producers Allowed Tax Deduction On Appeal
- Trustee Flags 'Broad' Releases In Medical Device Firm's Ch. 11
- Feds Unveil Collaborative Push On Biologics Competition
- Bayer Gets Boost As It Preps For Roundup Showdown In Calif.
- Fenwick-Backed Life Sciences Co. Files For $125M IPO
- Strategic Considerations For Litigating Alice Issues At Trial
- 7 Ethics Questions To Ask Before Marketing Your Law Firm
- Womble Bond Nabs Health Care Ace From Nelson Mullins
- Latham, Davis Polk Guide Cancer Biotech's $150M IPO Launch
- NJ High Court Signals Support For Pfizer Arbitration Bid
- Product Liability Defense In The Last Decade — And The Next
- Pfizer Fights Chinese Drugmaker Over Chantix Generic
- Amgen Asks Fed. Circ. To Review Merck's $2.5B Patent Loss
- Fried Frank Assists On Catalent's $315M Deal For Masthercell
- Surescripts Says Conspiracy Claims Outline Valid Agreements
- Purell Sued For Claiming Hand Sanitizer Prevents Flu, Ebola
- Allergan Investors Seek Class Cert. In Implant Stock Drop Suit